Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Chuangyue Huikang (300451) as of February 5, 2026, showing a decline in stock price and significant net outflows from various investor categories [1][2]. Group 2 - Chuangyue Huikang reported a main revenue of 862 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 26.26% [2]. - The company experienced a net profit attributable to shareholders of -122 million yuan, a significant decline of 331.69% year-on-year [2]. - The net profit after deducting non-recurring items was -142 million yuan, down 382.12% year-on-year [2]. - In Q3 2025, the company’s single-quarter main revenue was 285 million yuan, reflecting a 35.5% year-on-year decrease [2]. - The single-quarter net profit attributable to shareholders was -41.67 million yuan, a decline of 264.2% year-on-year [2]. - The company’s debt ratio stands at 20.27%, with investment income of 4.44 million yuan and financial expenses of -5.32 million yuan, while the gross profit margin is 49.87% [2]. Group 3 - Chuangyue Huikang's main business has shifted from primarily product development and sales to a broader focus on system construction, services, and operations, including areas such as smart healthcare, internet medical services, medical IoT, health big data, smart health cities, and innovative operational services [2].

Group 1 - Company Chuangyue Huikang Technology Co., Ltd. won a procurement project from China Construction Bank Liaoning Branch with a bid amount of 1.8 million yuan [1] - In 2024, the company's operating revenue was 1.423 billion yuan, with a revenue growth rate of -11.96% [2][3] - The net profit attributable to the parent company for 2024 was -174 million yuan, with a net profit growth rate of -572.96% [2][3] Group 2 - In the first half of 2025, the company's operating revenue was 577 million yuan, with a revenue growth rate of -20.65% [2][3] - The net profit attributable to the parent company for the first half of 2025 was -81 million yuan, with a net profit growth rate of -394.25% [2][3] - The company operates in the information technology industry, with main product types including industry-specific software, service (39.86%), software sales (39.55%), system integration and operation maintenance (10.74%), and hardware sales and others (9.85%) [2][3]

Core Viewpoint - The company Chuangying Huikang (300451) has experienced significant declines in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations and financial health [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 862 million yuan, a year-on-year decrease of 26.26% [2]. - The net profit attributable to shareholders was -122 million yuan, reflecting a year-on-year decline of 331.69% [2]. - The net profit excluding non-recurring items was -142 million yuan, down 382.12% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 285 million yuan, a decrease of 35.5% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -41.67 million yuan, a decline of 264.2% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was -47.40 million yuan, down 288.66% year-on-year [2]. - The company's debt ratio stood at 20.27%, with investment income of 4.44 million yuan and financial expenses of -5.32 million yuan [2]. - The gross profit margin was reported at 49.87% [2]. Business Operations - The company's main business has shifted from primarily product development and sales to a broader focus on system construction, services, and operations [2]. - Key areas of expansion include smart healthcare, internet medical services, medical IoT, health big data, smart health cities, and innovative solutions for smart medical insurance [2].

Core Viewpoint - The company, Chuangye Huikang (300451), is currently in the process of planning a change in control, and there are no undisclosed matters as of now. The company will comply with relevant regulations for information disclosure if there are any updates [1]. Group 1 - The company is in the process of planning a change in control [1] - As of now, there are no undisclosed matters that need to be reported [1] - The company commits to strict compliance with information disclosure regulations for any future developments [1]

Core Viewpoint - The company expects a net loss attributable to shareholders of 305 million to 405 million yuan for the fiscal year 2025, compared to a loss of 174 million yuan in the same period last year [1] Group 1: Financial Performance - The company's loss situation has worsened during the reporting period, with a significant increase in expected losses [1] - The anticipated net loss for 2025 is projected to be between 305 million and 405 million yuan, indicating a decline in financial performance compared to the previous year's loss of 174 million yuan [1] Group 2: Operational Challenges - The company faces dual pressures on its operations due to the industry and policy environment, which has led to a temporary contraction in client investment in information technology [1] - The new generation HI-HIS product is currently in a critical phase of market introduction and adjustment, limiting its short-term contribution to performance, although long-term potential remains promising [1] - Changes in the competitive landscape have compressed the industry's profit margins, further impacting the company's financial health [1] Group 3: Strategic Investments - The company continues to invest heavily in its AI strategy, resulting in high research and development expenses that are negatively affecting short-term profit performance [1] - Some subsidiaries have not met expected profitability levels, leading to an anticipated goodwill impairment provision of approximately 100 million to 130 million yuan [1]

证券代码：300451 证券简称：创业慧康 公告编号：2026-003 创业慧康科技股份有限公司 创业慧康科技股份有限公司（以下简称"公司"）于 2025 年 4 月 14 日召开 第八届董事会第十四次会议，于 2025 年 5 月 29 日召开 2024 年年度股东大会， 审议通过了《关于续聘会计师事务所的议案》，同意续聘天健会计师事务所（特 殊普通合伙）（以下简称"天健"）担任公司 2025 年度财务审计机构和内部控 制审计机构，具体内容详见公司于 2025 年 4 月 15 日在巨潮资讯网上披露的《关 于续聘会计师事务所的公告》（公告编号：2025-013）。近日，公司收到天健出 具的《关于变更项目质量复核人的函》，现将具体情况公告如下： 一、本次变更的基本情况 天健作为公司 2025 年度财务报表和 2025 年末财务报告内部控制审计机构， 原委派肖瑞峰作为公司2025年度财务报表审计报告和2025年末财务报告内部控 制审计报告的项目质量复核人。由于肖瑞峰工作安排调整，现委派黎永键接替肖 瑞峰作为项目质量复核人。变更后的项目质量复核人为黎永键。 二、本次变更的项目质量复核人员相关信息 项目质量复核人： ...

Financial Performance - The company expects a net profit in the range of -405 million to -305 million CNY for the fiscal year 2025, compared to a net profit of -173.52 million CNY in the same period last year [4]. - The net profit after deducting non-recurring gains and losses is projected to be between -415 million and -315 million CNY, down from -192.06 million CNY year-on-year [4]. - The company faces increased losses due to a contraction in client investment in healthcare information technology, leading to a decline in operating revenue [6]. Product Development and Market Position - The new generation HI-HIS product has been deployed in over 100 hospitals across more than 20 provinces, but its short-term contribution to revenue is limited as it is still in the market introduction phase [7]. - The competitive landscape in the healthcare information technology sector has intensified, compressing profit margins due to aggressive pricing strategies from new entrants [8]. - The company has invested heavily in AI research and development, which has increased costs and further pressured profit margins amid declining revenues [8]. - An impairment test for goodwill is expected to result in a provision of approximately 100 million to 130 million CNY due to underperformance of certain subsidiaries [8]. Strategic Initiatives - The company is focusing on enhancing its core products and optimizing development processes to improve efficiency and quality [9]. - A partnership with Zhejiang University aims to establish a joint laboratory for AI in medicine, focusing on innovative applications and research [9]. - The company is implementing a comprehensive risk management system to address challenges in technology iteration, market competition, and talent retention [10].

云头条声明：如以上内容有误或侵犯到你公司、机构、单位或个人权益，请联系我们说明理由，我们会 配合，无条件删除处理。 云头条声明：如以上内容有误或侵犯到你公司、机构、单位或个人权益，请联系我们说明理由，我们会 配合，无条件删除处理。 ...

Group 1 - Company Chuangyue Huikang Technology Co., Ltd. won a procurement project for Shenzhen Third Children's Hospital with a bid amount of 9.37 million yuan [1][2] - In 2024, the company's operating revenue was 1.423 billion yuan, with a revenue growth rate of -11.96% and a net profit attributable to the parent company of -174 million yuan, reflecting a net profit growth rate of -572.96% [2][3] - For the first half of 2025, the company's operating revenue was 577 million yuan, with a revenue growth rate of -20.65% and a net profit attributable to the parent company of -81 million yuan, indicating a net profit growth rate of -394.25% [2][3] Group 2 - The company operates in the information technology industry, primarily focusing on industry-specific software [2][3] - The main composition of the company's 2024 revenue includes services (39.86%), software sales (39.55%), system integration and operation maintenance (10.74%), and hardware sales and others (9.85%) [2][3]

Group 1 - The stock of Chuangyue Huikang (300451) closed at 5.78 yuan on January 23, 2026, with an increase of 2.48% and a turnover rate of 5.8% [1] - The net outflow of main funds was 33.72 million yuan, accounting for 6.59% of the total transaction amount, while retail investors had a net inflow of 23.94 million yuan, representing 4.68% of the total [1][2] - In the last 90 days, one institution rated the stock as a buy, with an average target price of 6.05 yuan [3] Group 2 - For the first three quarters of 2025, Chuangyue Huikang reported a main revenue of 862 million yuan, a year-on-year decrease of 26.26%, and a net profit attributable to shareholders of -122 million yuan, down 331.69% [2] - The company's third-quarter revenue was 285 million yuan, a decline of 35.5% year-on-year, with a net profit of -41.67 million yuan, down 264.2% [2] - The company has shifted its main business focus from product development and sales to system construction, services, and operations, including areas such as smart healthcare, internet medical services, and health city solutions [2]